ScripNicox S.A. posted mostly favorable Phase III data from the first of two pivotal trials for its glaucoma/ocular hypertension eye drop NCX 470, but missed demonstrating superiority versus a comparator
ScripCell and gene therapy companies raised $10.7bn during the first half of 2020, exceeding the $9.8bn full-year total that the regenerative medicine sector raised in 2019. Venture capital financings in t